


Faculty



Paul Wischmeyer M.D., E.D.I.C., FASPEN, FCCM

Professor of Anesthesiology and Surgery Associate Vice Chair for Clinical Research Department of Anesthesiology Physician Director, TPN/Nutrition Support Service DUH Duke University School of Medicine Durham, NC, USA

Baxter

Conflicts of Interest



NIH Funding (Past/Pres)

• NIA, NIDDK, NIGMS, NHLBI

CIHR Funding

RE-ENERGIZE Trial

Mentee Research Grants

• ASPEN, IARS, FAER

Dept of Defense:

- RE-ENERGIZE Trial
- Cardiac Surgery Care

Industry Financial Relationships:

• Consultant/Grant Support: Abbott, Baxter, Cosmed, Fresenius, Musclesound, Nestle, Nutricia, Takeda


USMP/QNRG/20-0031 08/2020 © 2020 Baxter Healthcare Corporation


Baxter

3

<image><image><image><image><image><image><image><text>


Clinical Guidelines Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically III Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Stephen A. McClave, MD ¹⁷ ; Beth E. Taylor, RD, DCN ²⁷ ; Robert G. Martindale, MD, PB Malissa M. Warren, RD ⁴ ; Debbie R. Johnson, RN, MS ⁵ ; Carol Braunschweig, RD, PhD Mary S. McCarthy, RN, PhD ¹ ; Evangelia Davanos, PharmD ⁵ ; Todd W. Rice, MD, MSC Gail A. Cresci, RD, PhD ¹⁹ ; Jane M. Gervasio, PharmD ¹⁷ ; Todd W. Rice, MD, MSC Gail A. Cresci, RD, PhD ¹⁹ ; Larlen C. Gordon S. Sacks, PharmD ¹⁷ ; Pamela R. Roberts, MD ¹⁰ ; Charlene Compher, RD, PhD ¹⁴ ; and the Society of Critical C Medicine ¹ and the American Society for Parenteral and Enteral Nutrition ¹	;	Question: What is the best method for determining energy needs in the critically ill adult patient? A3a. We suggest the indirect calorimetry (IC) be used to determine energy requirements, when available and in the absence of variables that affect the accuracy of measurement
		Quality of Evidence: Very Low







IC Guided "Isocaloric Feeding" with Trend to Improved Short-term Mortality

Study or Subgroup	Hypocaloric Events	Nutrition Total	Isocaloric Events	Nutrition Total	Weight	Risk Ratio M—H, Random, 95% Cl	Year	Risk Ratio M—H, Random, 95% Cl
2.1.1 Studies using indirect calorimetry								
Singer 2011	31	65	21	65	8.4%	1.48 [0.96, 2.28]	2011	
Heidegger 2013	28	152	20	153	6.4%	1.41 [0.83, 2.39]	2013	
Petros 2016	10	46	12	54	3.7%	0.98 [0.47, 2.05]	2016	
Allingstrup 2017	21	99	20	100	6.1%	1.06 [0.61, 1.83]	2017	
Subtotal (95% CI)		362		372	24.5%	1.28 [0.98, 1.67]		
Total events	90		73					
Heterogeneity: r ² = 0.00; x ² = 1.51, df=3 (P=0.68); l ² =0%								
Test for overall effect: Z=1.80 (P=0.07)								
2.1.2 Studies without Indirect Calorimetry								
Desachy 2008	11	50	14	50	4.24%	0.79 [0.40, 1.56]	2008	
Arabi 2011	22	120	28	120	6.9%	0.79 [0.48, 1.29]	2011	
Casaer 2011	242	2328	251	2312	18.7%	0.96 [0.81, 1.13]	2011	+
Rice 2011	22	98	20	102	6.2%	1.14 [0.67, 1.96]	2011	
Rugles 2013	5	53	3	62	1.2%	1.95 [0.49, 0.78]	2013	
Charles 2014	3	41	4	42	1.1%	0.77 [0.18, 3.22]	2014	
Peake 2014	18	55	11	57	4.6%	1.70 [0.88, 3.26]	2014	
Doig 2015	15	166	30	165	5.5%	0.50 [0.28, 0.89]	2015	
Braunschweig 2015	6	38	16	40	3.1%	0.39 [0.17, 0.90]	2015	
Arabi 2015	93	447	97	444	14.6%	0.95 [0.74, 1.23]	2015	-
Rugles 2016	18	60	16	60	5.7%	1.13 [0.64, 1.99]	2016	
Wischmeyer 2017	17	73	8	52	3.6%	1.51 [0.71, 3.24]	2017	
Subtotal (95% CI)		3529		3506	75.5%	0.94 [0.78, 1.12]		•
Total events	472		498					
Heterogeneity: x ² = 0.03; x ² = 16.36, df=11 (P=0.13); I ² =33%								
Test for overall effect: Z=0.73 (P=0.47))								
Total (95% CI)		3891		3878	100.0%	1.01 [0/86, 1.18]		+
Total events	562		571					
Heterogeneity: 7 ² = 0.03; Chi ² = 22.06, df=15 (P=0.11); I ² =32%								0.2 0.5 1 2 5
Test for overall effect: Z=0.09 (P=0.93)								Favors Hypocaloric Favors Isocaloric
								<→
















	Clinical Nutrition	n xxx (2016) 1–12	
	Clinical	able at ScienceDirect Struct Nutrition ww.elsevier.com/locate/clnu	INICAL
In IC Tal	view direct calorimetry in nutritional thera ALIC study group ku Oshima ^a , Mette M. Berger ^b , Elisabeth De Wa uudia-Paula Heidegger ^g , Michael Hiesmayr ^h , Pie uude Pichard ^k . [*]	ele ^c , Anne Berit Guttormsen ^{d, e, f} ,	
Indirect Calorimetry is	Use is currently limited by	V Initiative was taken to	To be accurate, easy-to-

















IC in SCCM/ASPEN & ESPEN COVID-19 Updates SCCM/ASPEN Nutrition Therapy in the **ESPEN** expert statements and practical Patient with COVID-19 disease requiring ICU guidance for nutritional management of Care individuals with SARS-CoV-2 infection March 24, 2020 Updated April 1, 2020 Recommendation 4: Nutrition Dose, Advancing to Goal, and 2.2. Statement 2 Adjustments ... Energy needs can be assessed using indirect calorimetry if ... While energy requirements can ideally be determined by safely available with ensured sterility of the measurement indirect calorimetry, the principle of "clustering" of care is system, or as alternatives by prediction equations or weightparticularly important and we recommend instead using based formulae such as: weight-based equations to estimate energy requirements as a (1) 27 kcal per kg body weight and day; total energy expenditure for polymorbid patients aged >65 years (recommendation 4.2 in ref. [7]) practical matter for the COVID-19 patients ... (2) 30 kcal per kg body weight and day; total energy expenditure for severely underweight polymorbid patients (recommendation 4.3. in ref. [7])* (3) 30 kcal per kg body weight and day; guiding value for energy intake in older persons, this value should be individually adjusted with regard to nutritional status. physical activity level, disease status and tolerance (recommendation 1 in ref. [8]) In regards to IC, focus is on limiting physical exposure SCCM/ASPEN Nutrition Therapy in the Patient with COVID-19 disease requiring ICU Care, April, 2020 ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. March, 2020 Baxter 19 USMP/QNRG/20-0031 08/2020 © 2020 Baxter Healthcare Corporation

19



USMP/QNRG/20-0031 08/2020 © 2020 Baxter Healthcare Corporation 20

Indirect Calorimetry in COVID-19?

LEEP-COVID Study

LEEP-COVID is an ongoing trial. Results shown are preliminary and should not be considered definitive

Currently, no longitudinal data exist describing EE & metabolism of COVID-19 infection


Data urgently needed to assist care & recovery of COVID-19 patients worldwide





21

Baxter


<section-header><section-header><section-header><section-header><text><text><text>























Baseline Characteristics (n=22)	
Age (median, IQR)	58 (31-88)
Male sex - n (%)	13 (59)
Race - n (%)	
African-American/Black	12 (54)
Caucasian/White	7 (32)
• Hispanic	3 (14)
BMI (median, IQR)	30.7 (17.4-48.1)
BMI >30 (%)	12 (55)





ndirect Calorimetry / Nutrition Data:	D0-7	D7-14	D14-21	p-value
/leasured REE absolute kCal/day (all patients) (median, IQR)	1568 (1175-2215)	1830 (1465-2467)	2789 (1776-3262)	<0.05
Neasured REE kCal/kg Actual BW (BMI<30) (median, IQR)	19.2 (16.9-20.7)	26 (24.5-35.5)	29 (23-34.5)	<0.05
leasured REE kCal/kg Actual BW (BMI >30) (median, IQR)	17.5 (12-19.25)	21 (20-23.5)	31.5 (24.8-36)	<0.05
leasured REE kCal/kg Adjusted BW (BMI >30) (median, IQR)	20 (17-22.5)	26.3 (24-29)	32.5 (28.8-35.8)	<0.05
leasured REE kCal/kg Actual BW (all patients) (median, IQR)	19 (13.7-28.5)	26 (22-42)	30.4 (27-35.8)	<0.05
Actual kcal administered - kCal/kg (median, IQR)	9.4 (0.6-14.5)	13.5 (11-24)	26.5 (13.8-29.5)	<0.05
6 energy needs actually delivered as determined y measured REE (IBW) (median, IQR)	49.4 (27-58.8)	51.9 (41.5-88.5)	84.1 (83-98.1)	<0.05

























Clinical Data	D0-7	D7-14	D14 04	nyoluo
	D0-7	D7-14	014-21	p-value
Jse of prone positioning	12.3	7	12.2	0.17
%) (mean,sd)	(8.6)	(2.4)	(4.3)	0.17
Jse of paralysis with neuromuscular blocke	14.8	9.7	12.3	0.0
%) (mean, sd)	(8)	(1.7)	12.2 (4.3)	0.2
SOFA score	9	9	9.5	0.5
mean, sd)	(3.6) (3.2) (3.6)	0.5		







Indirect Calorimetry Data in COVID-19

NCT:04350073

Initial LEEP-COVID Data

First ICU Week

~20 kcal/kg (Actual BW for BMI < 30 and Adjusted BW for Obese BMI 30-50) are close to mREE

Acute Phase (First 1-5 days?)

Per ESPEN Guidelines would feed 70% of ~20 kcal to prevent overfeeding in non-malnourished pts

* Accepted for publication in Critical Care

Baxter

45



Indirect Calorimetry Data in COVID-19 NCT:04350073

Initial LEEP-COVID Data

After day 7

Considerable variability from day to day exists


Key Factors To Consider in Setting Goals


- Age: (Over 70= \ kcal/kg/d)
- Obesity: (30-32 kcal/kg/d IBW: post-1st ICU wk)
- Fever: Significant † kcals (500-1000 kcal/d)


* Accepted for publication in Critical Care

Baxter

















Clinical recommendations and integration of Indirect Calorimetry and the second second

1. McClave SA, et al. JPEN J Parenter Enteral Nutr. 2016;40(2):159-211. 2. Singer P, et al. Clin Nutr. 2019;38(1):48-79. 3. Zusman O, et al. Crit Care. 2016;20(1):367. 4. Oshima T, et al. Clin Nutr. 2017;36(3):651-662. <image><image>

Longitudinal Energy Expenditure and Metabolic Pathophysiology of COVID-19 (LEEP-COVID)

ClinicalTrials.gov Identifier: NCT04350073

https://clinicaltrials.gov/ct2/show/NCT04350073?term=Paul+Wisc hmeyer&cond=Covid19&draw=2&rank=2

Prospective, observational cohort study of 120 patients

Study Questions:

We propose to evaluate longitudinal metabolic and cardiac pathophysiology in patients with COVID-19 to understand, guide and optimize our metabolic clinical care during acute hospitalization.

Further, this data will be essential in providing objective data to guide physical recovery interventions including nutrition delivery and physical therapy to ensure functional recovery of COVID-19 patients.

We hypothesize:

COVID-19 will lead to significant, EE/metabolic changes, systemic mitochondrial dysfunction, significant muscle wasting and loss of function throughout the course of illness and during recovery.

Metabolic needs will initially decrease in acute illness and subsequently increase as patients transition from the acute phase of COVID illness to recovery phases. This data will guide nutrition and metabolic/clinical care in all phases of COVID-19 care where, for example, over-and under-feeding may pose risk to patient outcome.

Loss of muscle mass and physical function occurring in COVID-19 will significantly affect nutritional/rehabilitative/recovery of function/qol needs and requires addressing to personalize care to optimize clinical and functional recovery efforts in older COVID-19 patients.


USMP/QNRG/20-0031 08/2020 © 2020 Baxter Healthcare Corporation 53

53

Baxter

Q-NRG+ Metabolic Monitor Indications and Instructions for Use

The Q-NRG+ portable Metabolic Monitors are indicated for the measurement of Resting Energy Expenditure (REE) for spontaneously breathing and ventilated patients, within the following populations:



Spontaneously breathing subjects age >6 yrs and > 10 kg (22 lb) when using a face mask

Ventilated subjects age > 10 yrs and > 10 kg (22 lb)

The Q-NRG+ Portable Metabolic Monitors are **intended to be** used in professional healthcare facilities only.

> CE 0476

Baxter is a registered trademark of Baxter International Inc.

Q-NRG+ is a registered trademark of COSMED.

Baxter Healthcare Corporation One Baxter Parkway Deerfield, IL 60015 www.baxter.com Precautions/Contraindications: Carefully re-check ventilator functionality after connection of the ports. Make sure that the patients cuff pressure is high enough to avoid air leakage. Manipulation of the ventilator circuit may cause leaks that may lower alveolar ventilation.

Indications for Use: The Q-NRG+ portable Metabolic Monitors are indicated for the measurement of REE for spontaneously breathing and ventilated patients, with some limitations in accordance with labeling, within the following population: spontaneously breathing subjects > 15 Kg (33 lb), when tested with the canopy dilution technique, ventilated subjects > age 10 and 10 Kg (22 lb), and spontaneously breathing subjects > age 6 and 10 Kg (22 lb), when tested with face mask. The Q-NRG+ Portable Metabolic Monitors are intended to be used in professional healthcare facilities only. This device is not suitable for operating in presence of flammable anesthetic gases or gases other than 02, C02, N2 and water vapor. The device is not suitable for operating under the responsibility of a physician. The device is not intended as a continuous monitoring device for surveillance of vital physiological processes.

Warnings: This devices measures clinical parameters used to aid diagnosis and it is intended only as an adjunct device in patient assessment. In case of disturbing conditions, the shutdown is allowed because the safety of the device towards patients and operators is not affected, since the final evaluation is performed on the outcome data measured during a complete test. No modification of this device is allowed.

Rx Only. For safe and proper use of this device please refer to the User's Manual.

USMP/QNRG/20-0031 08/2020 © 2020 Baxter Healthcare Corporation 54